AI Article Synopsis
- Radioiodine therapy with (131)I is used to treat suspected recurrence of thyroid cancer, and low-activity (124)I PET/CT scans are conducted beforehand to predict treatment success.
- The study aimed to investigate discrepancies in lesion detectability between (124)I PET/CT and (131)I SPECT/CT by calculating a metric called detectability equivalence percentage (DEP).
- Results showed that a low (124)I activity of 74 MBq can achieve similar detection for small lesions compared to (131)I SPECT/CT, especially for spheres 10 mm or smaller, indicating that false negatives from (124)I scans are less likely for these sizes.
Article Abstract
Unlabelled: Radioiodine therapy with (131)I is used for treatment of suspected recurrence of differentiated thyroid carcinoma. Pretherapeutic (124)I PET/CT with a low activity (~1% of (131)I activity) can be performed to determine whether uptake of (131)I, and thereby the desired therapeutic effect, may be expected. However, false-negative (124)I PET/CT results as compared with posttherapeutic (131)I SPECT/CT have been reported by several groups. The purpose of this study was to investigate whether the reported discrepancies may be ascribed to a difference in lesion detectability between (124)I PET/CT and (131)I SPECT/CT and, hence, whether the administered (124)I activity is sufficient to achieve equal detectability.
Methods: Phantom measurements were performed using the National Electrical Manufacturers Association 2007 image-quality phantom. As a measure of detectability, the contrast-to-noise ratio was calculated. The (124)I activity was expressed as the percentage of (131)I activity required to achieve the same contrast-to-noise ratio. This metric was defined as the detectability equivalence percentage (DEP).
Results: Because lower DEPs were obtained for smaller spheres, a relatively low (124)I activity was sufficient to achieve similar lesion detectability between (124)I PET/CT and (131)I SPECT/CT. DEP was 1.5%, 1.9%, 1.9%, 4.4%, 9.0%, and 16.2% for spheres with diameters of 10, 13, 17, 18, 25, and 37 mm, respectively, for attenuation- and scatter-corrected SPECT versus point-spread function (PSF) model-based and time-of-flight (TOF) PET. For no-PSF no-TOF PET, DEP was 3.6%, 2.1%, 3.5%, 7.8%, 15.1%, and 23.3%, respectively.
Conclusion: A relatively low (124)I activity of 74 MBq (~1% of (131)I activity) is sufficient to achieve similar lesion detectability between (124)I PSF TOF PET/CT and (131)I SPECT/CT for small spheres (≤10 mm), since the reported DEPs are close to 1%. False-negative (124)I PET/CT results as compared with posttherapeutic (131)I SPECT/CT may be ascribed to differences in detectability for large lesions (>10 mm) and for no-PSF no-TOF PET, since DEPs are greater than 1%. On the basis of DEPs of 3.5% for lesion diameters of up to 17 mm on no-PSF no-TOF PET, (124)I activities as high as 170 MBq may be warranted to obtain equal detectability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.115.162750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]TFB PET/CT misses intense [I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.
EJNMMI Res
October 2024
Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P.O. Box 77, New York, NY, 10065, USA.
Article Synopsis
- The study investigates the effectiveness of Fluorine 18-labelled tetrafluoroborate ([F]TFB) as an imaging alternative to iodine for assessing metastatic thyroid cancer and potential radioiodine treatment success.
- Five patients participated in the research, receiving both [F]TFB and iodine imaging on the same day. Results showed that [F]TFB identified 58% of lesions compared to 91% for iodine imaging, indicating its lower sensitivity.
- The conclusion drawn highlights that [F]TFB did not successfully predict iodine uptake in patients undergoing redifferentiation therapy, raising questions about its reliability for other treatment cases or in untreated patients.
Construction and preclinical evaluation of a I-labelled bispecific antibody targeting PD-L1 and PD-L2.
Eur J Nucl Med Mol Imaging
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, No. 52 Fu-Cheng Rd, Beijing, 100142, People's Republic of China.
Article Synopsis
- The study focused on developing a bispecific antibody, NB12, that targets PD-L1 and PD-L2, aimed at monitoring cancer patient responses to immune checkpoint inhibitors (ICI) through a radiotracer called [I]I-NB12.
- In vitro testing showed that [I]I-NB12 had a high affinity for its targets, was effectively taken up by certain cancer cells, and demonstrated favorable pharmacokinetics.
- Micro-PET/CT imaging indicated that [I]I-NB12 successfully accumulated in tumor regions, confirming its potential for dynamic imaging in cancer diagnostics.
Theranostic Intratumoral Convection-Enhanced Delivery of I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
J Nucl Med
September 2024
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody.
View Article and Find Full Text PDFSynthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Mol Pharm
May 2024
Shanghai Institute of Medical Imaging, Shanghai 200032, China.
Article Synopsis
- - Chemokines, particularly the CXCR4 receptor, are crucial in tumor development, and targeting CXCR4 with radioligands like [Ga]Ga-pentixafor holds promising potential for cancer diagnostics and therapy.
- - The study aimed to create improved molecular tracers for CXCR4, synthesizing six new tracers, with [I]I-6 demonstrating the highest targeting efficiency and the best target-nontarget ratio after imaging tests.
- - In trials on tumor-bearing animal models, treatment with [I]I-6 significantly reduced tumor size without notable side effects, highlighting its effectiveness in targeting CXCR4 in cancer therapy.
Preclinical evaluation of Tc-99m p5+14 peptide for SPECT detection of cardiac amyloidosis.
PLoS One
April 2024
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, United States of America.
Introduction: Amyloid deposition is a cause of restrictive cardiomyopathy. Patients who present with cardiac disease can be evaluated for transthyretin (TTR)-associated cardiac amyloidosis using nuclear imaging with 99mTc-labeled pyrophosphate (PYP); however, light chain-associated (AL) cardiac amyloid is generally not detected using this tracer. As an alternative, the amyloid-binding peptide p5+14 radiolabeled with iodine-124 has been shown to be an effective pan-amyloid radiotracer for PET/CT imaging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!